^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    vebreltinib (APL-101)

    i
    Other names: APL-101, PLB-1001, CBI-3103, PLB1001, CBT 101, CBT-101, APL101
    Company:
    Apollomics, Avistone Biotech, LaunXP Biomedical
    Drug class:
    c-MET inhibitor
    Related drugs:
    Apply
    A Study of PLB1001 in Non-small Cell Lung Cancer With c-Met Dysregulation(KUNPENG) (NCT04258033)
    Phase 2
    Beijing Pearl Biotechnology Limited Liability C...
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    01/17/2020
    Primary completion :
    05/14/2024
    Completion :
    12/31/2025
    MET
    |
    vebreltinib (APL-101)
    A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2) (NCT05989542)
    Phase 3
    Beijing Pearl Biotechnology Limited Liability C...
    Recruiting
    Last update posted :
    02/06/2025
    Initiation :
    06/29/2023
    Primary completion :
    09/30/2026
    Completion :
    09/30/2027
    EGFR • KRAS • ALK • MET • ROS1
    |
    ALK rearrangement • EGFR wild-type • MET exon 14 mutation • ROS1 rearrangement
    |
    vebreltinib (APL-101)
    Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion (NCT06739395)
    Phase 2
    Tianjin Medical University Second Hospital
    Recruiting
    Last update posted :
    12/18/2024
    Initiation :
    11/01/2024
    Primary completion :
    12/31/2026
    Completion :
    05/01/2027
    BRAF
    |
    Lynparza (olaparib) • Mekinist (trametinib) • Ibrance (palbociclib) • Tafinlar (dabrafenib) • Focus V (anlotinib) • temozolomide • Lenvima (lenvatinib) • Piqray (alpelisib) • pazopanib • Epidaza (chidamide) • Trodelvy (sacituzumab govitecan-hziy) • vebreltinib (APL-101)
    APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA) (NCT03175224)
    Phase 2
    Apollomics Inc.
    Recruiting
    Last update posted :
    05/10/2024
    Initiation :
    09/27/2017
    Primary completion :
    03/30/2026
    Completion :
    11/30/2026
    HGF • PTPRZ1
    |
    EGFR mutation • MET amplification • EGFR wild-type • MET exon 14 mutation • MET overexpression • MET expression • EGFR positive • MET fusion
    |
    vebreltinib (APL-101) • CBT101
    Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) (NCT04743505)
    Phase 1/2
    Washington University School of Medicine
    Recruiting
    Last update posted :
    04/25/2024
    Initiation :
    01/18/2022
    Primary completion :
    09/30/2027
    Completion :
    09/30/2029
    EGFR
    |
    EGFR mutation
    |
    Tagrisso (osimertinib) • vebreltinib (APL-101)
    Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas (NCT02978261)
    Phase 1
    Beijing Pearl Biotechnology Limited Liability C...
    Completed
    Last update posted :
    03/04/2020
    Initiation :
    09/01/2016
    Primary completion :
    04/01/2018
    Completion :
    12/01/2018
    PTPRZ1
    |
    vebreltinib (APL-101)
    First-in-human Phase I Study of a Selective c-Met Inhibitor PLB1001 (NCT02896231)
    Phase 1
    Beijing Pearl Biotechnology Limited Liability C...
    Completed
    Last update posted :
    11/22/2019
    Initiation :
    04/01/2016
    Primary completion :
    10/01/2019
    Completion :
    10/01/2019
    MET
    |
    vebreltinib (APL-101)